Could a Stop-Smoking drug fight dialysis fatigue?

NCT ID NCT06609343

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests whether bupropion, a medicine used for smoking cessation and depression, can reduce severe tiredness in people with end-stage kidney disease on dialysis. Sixteen participants will take bupropion three times a week for 8 weeks and report their fatigue levels. The goal is to find a safe, effective way to improve quality of life for these patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure Fatigue

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital Dialysis Medical Center (DMC)

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••